Literature DB >> 32379366

Fgfr3 Is a Positive Regulator of Osteoblast Expansion and Differentiation During Zebrafish Skull Vault Development.

Emilie Dambroise1, Ivan Ktorza1, Alessandro Brombin2,3, Ghaith Abdessalem4, Joanne Edouard5,6, Marine Luka4, Imke Fiedler7, Olivia Binder1, Olivier Pelle8, E Elizabeth Patton2,3, Björn Busse7, Mickaël Menager4, Frederic Sohm5,6,7,8,9, Laurence Legeai-Mallet1.   

Abstract

Gain or loss-of-function mutations in fibroblast growth factor receptor 3 (FGFR3) result in cranial vault defects highlighting the protein's role in membranous ossification. Zebrafish express high levels of fgfr3 during skull development; in order to study FGFR3's role in cranial vault development, we generated the first fgfr3 loss-of-function zebrafish (fgfr3lof/lof ). The mutant fish exhibited major changes in the craniofacial skeleton, with a lack of sutures, abnormal frontal and parietal bones, and the presence of ectopic bones. Integrated analyses (in vivo imaging and single-cell RNA sequencing of the osteoblast lineage) of zebrafish fgfr3lof/lof revealed a delay in osteoblast expansion and differentiation, together with changes in the extracellular matrix. These findings demonstrate that fgfr3 is a positive regulator of osteogenesis. We conclude that changes in the extracellular matrix within growing bone might impair cell-cell communication, mineralization, and new osteoblast recruitment.
© 2020 American Society for Bone and Mineral Research. © 2020 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CRANIAL VAULT DEFECTS; FGFR3; OSTEOBLASTS; OSTEOGENESIS

Mesh:

Substances:

Year:  2020        PMID: 32379366     DOI: 10.1002/jbmr.4042

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  6 in total

Review 1.  Functional Validation of Osteoporosis Genetic Findings Using Small Fish Models.

Authors:  Erika Kague; David Karasik
Journal:  Genes (Basel)       Date:  2022-01-30       Impact factor: 4.096

2.  Computational prediction of small molecules with predicted binding to FGFR3 and testing biological effects in bone cells.

Authors:  Subburaman Mohan; Karthikeyan Muthusamy; Selvaraman Nagamani; Chandrasekhar Kesavan
Journal:  Exp Biol Med (Maywood)       Date:  2021-03-27

3.  FGFR3 overactivation in the brain is responsible for memory impairments in Crouzon syndrome mouse model.

Authors:  Maxence Cornille; Stéphanie Moriceau; Roman H Khonsari; Yann Heuzé; Léa Loisay; Valérie Boitez; Anne Morice; Eric Arnaud; Corinne Collet; Morad Bensidhoum; Nabil Kaci; Nathalie Boddaert; Giovanna Paternoster; Theresa Rauschendorfer; Sabine Werner; Suzanne L Mansour; Federico Di Rocco; Franck Oury; Laurence Legeai-Mallet
Journal:  J Exp Med       Date:  2022-03-07       Impact factor: 17.579

Review 4.  Perspective of the GEMSTONE Consortium on Current and Future Approaches to Functional Validation for Skeletal Genetic Disease Using Cellular, Molecular and Animal-Modeling Techniques.

Authors:  Martina Rauner; Ines Foessl; Melissa M Formosa; Erika Kague; Vid Prijatelj; Nerea Alonso Lopez; Bodhisattwa Banerjee; Dylan Bergen; Björn Busse; Ângelo Calado; Eleni Douni; Yankel Gabet; Natalia García Giralt; Daniel Grinberg; Nika M Lovsin; Xavier Nogues Solan; Barbara Ostanek; Nathan J Pavlos; Fernando Rivadeneira; Ivan Soldatovic; Jeroen van de Peppel; Bram van der Eerden; Wim van Hul; Susanna Balcells; Janja Marc; Sjur Reppe; Kent Søe; David Karasik
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-30       Impact factor: 5.555

Review 5.  The genetic overlap between osteoporosis and craniosynostosis.

Authors:  Erika Kague; Carolina Medina-Gomez; Simeon A Boyadjiev; Fernando Rivadeneira
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-26       Impact factor: 6.055

6.  Meclozine Attenuates the MARK Pathway in Mammalian Chondrocytes and Ameliorates FGF2-Induced Bone Hyperossification in Larval Zebrafish.

Authors:  Genta Takemoto; Masaki Matsushita; Takaaki Okamoto; Toshinari Ito; Yuki Matsuura; Chieko Takashima; Toyofumi Fengshi Chen-Yoshikawa; Hiromichi Ebi; Shiro Imagama; Hiroshi Kitoh; Kinji Ohno; Yasuyuki Hosono
Journal:  Front Cell Dev Biol       Date:  2022-01-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.